Allterum, FujiFilm begin development, scale-up of monoclonal antibodies for leukemia

By The Science Advisory Board staff writers

April 21, 2020 -- Allterum Therapeutics has received a $2.9 million product development grant from the Cancer Research and Prevention Institute of Texas to support preclinical development of monoclonal antibodies for leukemia.

Specifically, the funds will be used to support preclinical development of 4A10 antibody therapy for the treatment of pediatric patients suffering from T-cell acute lymphoblastic leukemia, according to the company. This technology was licensed from the U.S. National Cancer Institute.

In addition, the funding will be utilized to support the drug manufacturing scale-up currently underway in partnership with contract development and manufacturing organization Fujifilm Diosynth Biotechnologies, Allterum said.

Copyright © 2020
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here